Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $413.49 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $123.00 | 1 | $0 (2019) |
| EMD Serono, Inc. | $94.11 | 3 | $0 (2019) |
| SK Life Science, Inc. | $87.52 | 1 | $0 (2021) |
| Greenwich Biosciences, Inc. | $58.27 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $34.01 | 2 | $0 (2017) |
| Allergan Inc. | $16.58 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $87.52 | 1 | SK Life Science, Inc. ($87.52) |
| 2019 | $275.38 | 5 | Sunovion Pharmaceuticals Inc. ($123.00) |
| 2017 | $50.59 | 3 | Novartis Pharmaceuticals Corporation ($34.01) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/23/2021 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $87.52 | General |
| Category: Neurology | ||||||
| 10/08/2019 | Greenwich Biosciences, Inc. | Epidiolex (Drug) | Food and Beverage | In-kind items and services | $58.27 | General |
| Category: Neurology | ||||||
| 09/05/2019 | EMD Serono, Inc. | Mavenclad (Biological) | Food and Beverage | In-kind items and services | $51.69 | General |
| Category: Neurology | ||||||
| 07/31/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $123.00 | General |
| Category: CNS | ||||||
| 07/26/2019 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $21.21 | General |
| 07/26/2019 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $21.21 | General |
| 08/09/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: NEUROSCIENCE | ||||||
| 03/08/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: NEUROSCIENCE | ||||||
| 02/28/2017 | Allergan Inc. | BOTOX THERAPEUTIC (Biological) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: HYPERHYDROSIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 270 | 319 | $84,912 | $22,355 |
| 2022 | 6 | 265 | 327 | $88,855 | $22,593 |
| 2021 | 8 | 283 | 350 | $93,045 | $23,700 |
| 2020 | 10 | 261 | 296 | $92,517 | $21,414 |
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 68 | 68 | $27,404 | $6,377 | 23.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 71 | 105 | $22,470 | $6,300 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 57 | 57 | $18,411 | $5,192 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 33 | $10,131 | $2,419 | 23.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 44 | 56 | $6,496 | $2,067 | 31.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 77 | 77 | $31,031 | $7,638 | 24.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 70 | 118 | $25,252 | $6,100 | 24.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 61 | 61 | $19,703 | $5,707 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 17 | $5,219 | $1,236 | 23.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 27 | 40 | $4,640 | $1,154 | 24.9% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 13 | 14 | $3,010 | $758.15 | 25.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 83 | 84 | $33,852 | $8,192 | 24.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 52 | 83 | $17,762 | $4,526 | 25.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 38 | 38 | $12,274 | $3,963 | 32.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 29 | 31 | $9,517 | $2,367 | 24.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 34 | 66 | $7,656 | $1,804 | 23.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 17 | 17 | $5,083 | $1,289 | 25.3% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 18 | 19 | $3,249 | $790.38 | 24.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 12 | 12 | $3,652 | $768.72 | 21.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 65 | 65 | $26,195 | $6,748 | 25.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 59 | 87 | $18,618 | $4,767 | 25.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 33 | 33 | $15,609 | $3,091 | 19.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $7,761 | $1,875 | 24.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 18 | 18 | $5,382 | $1,287 | 23.9% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 23 | 23 | $7,084 | $1,167 | 16.5% |
About Richard Ronca
Richard Ronca is a Neurology healthcare provider based in Cape Girardeau, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2015. The National Provider Identifier (NPI) number assigned to this provider is 1437544749.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Richard Ronca has received a total of $413.49 in payments from pharmaceutical and medical device companies, with $87.52 received in 2021. These payments were reported across 9 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($413.49).
As a Medicare-enrolled provider, Ronca has provided services to 1,079 Medicare beneficiaries, totaling 1,292 services with total Medicare billing of $90,061. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Cape Girardeau, MO
- Active Since 04/02/2015
- Last Updated 02/26/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1437544749
Products in Payments
- APTIOM (Drug) $123.00
- XCOPRI (Drug) $87.52
- Epidiolex (Drug) $58.27
- Mavenclad (Biological) $51.69
- GILENYA (Drug) $34.01
- BOTOX THERAPEUTIC (Biological) $16.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Cape Girardeau
Robert Gardner, Md, MD
Neurology — Payments: $103,392
David Lee, Md, MD
Neurology — Payments: $23,480
Dr. Randall Stahly, D.o, D.O
Neurology — Payments: $8,008
James Laguardia, M.d, M.D
Neurology — Payments: $4,860
Dr. Aleksey Androsov, M.d, M.D
Neurology — Payments: $4,536
Dr. Mark Farrenburg, M.d, M.D
Neurology — Payments: $2,221